uploads/2015/11/Graph-Part-2-Nov-9-20151.png

Becton Led IHI’s Large-Cap Stocks Last Week

By

Updated

Reviewing the performances of large-cap stocks for the week

The large-cap stocks had a mixed week. For the week ended November 6, 2015, the large-cap stocks of the iShares US Medical Devices ETF (IHI) outperformed the other biotech ETFs in the large-cap space. IHI’s large-cap stocks gave an average return of 2.4% for the week ended November 6, 2015. The large-cap stocks of the iShares Nasdaq Biotechnology ETF (IBB) were the worst performers with a return of -1.75% for the same period.

Article continues below advertisement

The graph reflects the performances of the large-cap stocks of different biotech ETFs on a week-over-week basis. Since the week ended October 23, 2015, IBB large-cap stocks have returned 3.4%, IHI large-cap stocks rose by 5.2%, the SPDR S&P Biotechnology ETF (XBI) went up by 6.5%, and the Health Care Select Sector SPDR ETF (XLV) returned 2.5%.

Becton was the top performer among IHI large-cap stocks

Becton Dickinson (BDX) gained 7% for the week ended November 6, 2015. BDX announced its 4Q15 and its full-year earnings. For the full year 2015, it reported revenues of $10.3 billion, an increase of 21.7% compared to 2014. It reported diluted EPS (earnings per share) of $3.35 for the full year 2015 as compared to $5.99 for the prior year. Investors were excited about the revenue growth. However, BDX’s net income for the full year went down by 41.3% compared to 2014. This was mainly due to an increase in operating costs of 34.6% on a year-over-year basis.

In its 2016 guidance, the company said it expects revenues to grow in the range of 23% to 23.5%. It expects the full fiscal year diluted earnings per share to be between $6.57 and $6.64.

The other large-cap stocks that performed well were AbbVie (ABBV) and Cardinal Health (CAH), which gave returns of 7.7% and 7.65%, respectively. Incyte (INCY) was the worst-performing stock with a negative return of 14.8% for the week ended November 6, 2015.

Advertisement

More From Market Realist